Semisynthetic, broad-spectrum antibacterial derived from CEPHALORIDINE and used especially for Pseudomonas and other gram-negative infections in debilitated patients.
A group of broad-spectrum antibiotics first isolated from the Mediterranean fungus ACREMONIUM. They contain the beta-lactam moiety thia-azabicyclo-octenecarboxylic acid also called 7-aminocephalosporanic acid.
Enzymes found in many bacteria which catalyze the hydrolysis of the amide bond in the beta-lactam ring. Well known antibiotics destroyed by these enzymes are penicillins and cephalosporins.
A monocyclic beta-lactam antibiotic originally isolated from Chromobacterium violaceum. It is resistant to beta-lactamases and is used in gram-negative infections, especially of the meninges, bladder, and kidneys. It may cause a superinfection with gram-positive organisms.
Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses).
Substances that reduce the growth or reproduction of BACTERIA.
A species of gram-negative, aerobic, rod-shaped bacteria commonly isolated from clinical specimens (wound, burn, and urinary tract infections). It is also found widely distributed in soil and water. P. aeruginosa is a major agent of nosocomial infection.
Non-susceptibility of an organism to the action of the cephalosporins.
Semisynthetic broad-spectrum cephalosporin.
Beta-lactam antibiotics that differ from PENICILLINS in having the thiazolidine sulfur atom replaced by carbon, the sulfur then becoming the first atom in the side chain. They are unstable chemically, but have a very broad antibacterial spectrum. Thienamycin and its more stable derivatives are proposed for use in combinations with enzyme inhibitors.
Four-membered cyclic AMIDES, best known for the PENICILLINS based on a bicyclo-thiazolidine, as well as the CEPHALOSPORINS based on a bicyclo-thiazine, and including monocyclic MONOBACTAMS. The BETA-LACTAMASES hydrolyze the beta lactam ring, accounting for BETA-LACTAM RESISTANCE of infective bacteria.
A broad-spectrum antibiotic derived from KANAMYCIN. It is reno- and oto-toxic like the other aminoglycoside antibiotics.
Semisynthetic thienamycin that has a wide spectrum of antibacterial activity against gram-negative and gram-positive aerobic and anaerobic bacteria, including many multiresistant strains. It is stable to beta-lactamases. Clinical studies have demonstrated high efficacy in the treatment of infections of various body systems. Its effectiveness is enhanced when it is administered in combination with CILASTATIN, a renal dipeptidase inhibitor.
Monocyclic, bacterially produced or semisynthetic beta-lactam antibiotics. They lack the double ring construction of the traditional beta-lactam antibiotics and can be easily synthesized.
Semisynthetic, broad-spectrum, AMPICILLIN derived ureidopenicillin antibiotic proposed for PSEUDOMONAS infections. It is also used in combination with other antibiotics.
Infections with bacteria of the genus PSEUDOMONAS.
Gram-negative, non-motile, capsulated, gas-producing rods found widely in nature and associated with urinary and respiratory infections in humans.
Bacteria which lose crystal violet stain but are stained pink when treated by Gram's method.
A building block of penicillin, devoid of significant antibacterial activity. (From Merck Index, 11th ed)
A disease of humans and animals that resembles GLANDERS. It is caused by BURKHOLDERIA PSEUDOMALLEI and may range from a dormant infection to a condition that causes multiple abscesses, pneumonia, and bacteremia.
Semisynthetic broad-spectrum cephalosporin with a tetrazolyl moiety that is resistant to beta-lactamase. It has been proposed especially against Pseudomonas infections.
Bicyclic bridged compounds that contain a nitrogen which has three bonds. The nomenclature indicates the number of atoms in each path around the rings, such as [2.2.2] for three equal length paths. Some members are TROPANES and BETA LACTAMS.
Nonsusceptibility of bacteria to the action of the beta-lactam antibiotics. Mechanisms responsible for beta-lactam resistance may be degradation of antibiotics by BETA-LACTAMASES, failure of antibiotics to penetrate, or low-affinity binding of antibiotics to targets.
The ability of microorganisms, especially bacteria, to resist or to become tolerant to chemotherapeutic agents, antimicrobial agents, or antibiotics. This resistance may be acquired through gene mutation or foreign DNA in transmissible plasmids (R FACTORS).
A family of gram-negative, facultatively anaerobic, rod-shaped bacteria that do not form endospores. Its organisms are distributed worldwide with some being saprophytes and others being plant and animal parasites. Many species are of considerable economic importance due to their pathogenic effects on agriculture and livestock.
An aminoglycoside, broad-spectrum antibiotic produced by Streptomyces tenebrarius. It is effective against gram-negative bacteria, especially the PSEUDOMONAS species. It is a 10% component of the antibiotic complex, NEBRAMYCIN, produced by the same species.
A species of gram-negative, aerobic bacteria that causes MELIOIDOSIS. It has been isolated from soil and water in tropical regions, particularly Southeast Asia.
Infections with bacteria of the family ENTEROBACTERIACEAE.
Infections with bacteria of the genus KLEBSIELLA.
A species of gram-negative, facultatively anaerobic, rod-shaped bacteria that occurs in water, sewage, soil, meat, hospital environments, and on the skin and in the intestinal tract of man and animals as a commensal.
Inflammation of the lung parenchyma that is associated with BRONCHITIS, usually involving lobular areas from TERMINAL BRONCHIOLES to the PULMONARY ALVEOLI. The affected areas become filled with exudate that forms consolidated patches.
Infections by bacteria, general or unspecified.
Clavulanic acid and its salts and esters. The acid is a suicide inhibitor of bacterial beta-lactamase enzymes from Streptomyces clavuligerus. Administered alone, it has only weak antibacterial activity against most organisms, but given in combination with other beta-lactam antibiotics it prevents antibiotic inactivation by microbial lactamase.
Infections caused by bacteria that show up as pink (negative) when treated by the gram-staining method.
A broad-spectrum antimicrobial carboxyfluoroquinoline.
Broad- spectrum beta-lactam antibiotic similar in structure to the CEPHALOSPORINS except for the substitution of an oxaazabicyclo moiety for the thiaazabicyclo moiety of certain CEPHALOSPORINS. It has been proposed especially for the meningitides because it passes the blood-brain barrier and for anaerobic infections.
Electrophoresis in which a pH gradient is established in a gel medium and proteins migrate until they reach the site (or focus) at which the pH is equal to their isoelectric point.
Method of measuring the bactericidal activity contained in a patient's serum as a result of antimicrobial therapy. It is used to monitor the therapy in BACTERIAL ENDOCARDITIS; OSTEOMYELITIS and other serious bacterial infections. As commonly performed, the test is a variation of the broth dilution test. This test needs to be distinguished from testing of the naturally occurring BLOOD BACTERICIDAL ACTIVITY.
Therapy with two or more separate preparations given for a combined effect.
A decrease in the number of GRANULOCYTES; (BASOPHILS; EOSINOPHILS; and NEUTROPHILS).
A group of beta-lactam antibiotics in which the sulfur atom in the thiazolidine ring of the penicillin molecule is replaced by a carbon atom. THIENAMYCINS are a subgroup of carbapenems which have a sulfur atom as the first constituent of the side chain.
One of the three domains of life (the others being Eukarya and ARCHAEA), also called Eubacteria. They are unicellular prokaryotic microorganisms which generally possess rigid cell walls, multiply by cell division, and exhibit three principal forms: round or coccal, rodlike or bacillary, and spiral or spirochetal. Bacteria can be classified by their response to OXYGEN: aerobic, anaerobic, or facultatively anaerobic; by the mode by which they obtain their energy: chemotrophy (via chemical reaction) or PHOTOTROPHY (via light reaction); for chemotrophs by their source of chemical energy: CHEMOLITHOTROPHY (from inorganic compounds) or chemoorganotrophy (from organic compounds); and by their source for CARBON; NITROGEN; etc.; HETEROTROPHY (from organic sources) or AUTOTROPHY (from CARBON DIOXIDE). They can also be classified by whether or not they stain (based on the structure of their CELL WALLS) with CRYSTAL VIOLET dye: gram-negative or gram-positive.
The ability of bacteria to resist or to become tolerant to chemotherapeutic agents, antimicrobial agents, or antibiotics. This resistance may be acquired through gene mutation or foreign DNA in transmissible plasmids (R FACTORS).
A broad-spectrum cephalosporin antibiotic with a very long half-life and high penetrability to meninges, eyes and inner ears.
The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity.
Cyclic AMIDES formed from aminocarboxylic acids by the elimination of water. Lactims are the enol forms of lactams.
The ability of bacteria to resist or to become tolerant to several structurally and functionally distinct drugs simultaneously. This resistance may be acquired through gene mutation or foreign DNA in transmissible plasmids (R FACTORS).
A species of gram-negative, facultatively anaerobic, rod-shaped bacteria (GRAM-NEGATIVE FACULTATIVELY ANAEROBIC RODS) commonly found in the lower part of the intestine of warm-blooded animals. It is usually nonpathogenic, but some strains are known to produce DIARRHEA and pyogenic infections. Pathogenic strains (virotypes) are classified by their specific pathogenic mechanisms such as toxins (ENTEROTOXIGENIC ESCHERICHIA COLI), etc.
A beta-lactamase inhibitor with very weak antibacterial action. The compound prevents antibiotic destruction of beta-lactam antibiotics by inhibiting beta-lactamases, thus extending their spectrum activity. Combinations of sulbactam with beta-lactam antibiotics have been used successfully for the therapy of infections caused by organisms resistant to the antibiotic alone.
Bacteria which retain the crystal violet stain when treated by Gram's method.
An abnormal elevation of body temperature, usually as a result of a pathologic process.
Use of any infusion therapy on an ambulatory, outpatient, or other non-institutionalized basis.
Gram-negative gas-producing rods found in feces of humans and other animals, sewage, soil, water, and dairy products.
Suppurative inflammation of the tissues of the internal structures of the eye frequently associated with an infection.
A genus of gram-negative, facultatively anaerobic, rod-shaped bacteria whose organisms arrange singly, in pairs, or short chains. This genus is commonly found in the intestinal tract and is an opportunistic pathogen that can give rise to bacteremia, pneumonia, urinary tract and several other types of human infection.
An antibiotic derived from penicillin similar to CARBENICILLIN in action.
The long-term (minutes to hours) administration of a fluid into the vein through venipuncture, either by letting the fluid flow by gravity or by pumping it.
Injections made into a vein for therapeutic or experimental purposes.
A group of antibiotics that contain 6-aminopenicillanic acid with a side chain attached to the 6-amino group. The penicillin nucleus is the chief structural requirement for biological activity. The side-chain structure determines many of the antibacterial and pharmacological characteristics. (Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed, p1065)
A complex of closely related aminoglycosides obtained from MICROMONOSPORA purpurea and related species. They are broad-spectrum antibiotics, but may cause ear and kidney damage. They act to inhibit PROTEIN BIOSYNTHESIS.
The quality of not being miscible with another given substance without a chemical change. One drug is not of suitable composition to be combined or mixed with another agent or substance. The incompatibility usually results in an undesirable reaction, including chemical alteration or destruction. (Dorland, 27th ed; Stedman, 25th ed)
A pyridinium-substituted semisynthetic, broad-spectrum antibacterial used especially for Pseudomonas infections in debilitated patients.
Any infection which a patient contracts in a health-care institution.

Clindamycin suppresses endotoxin released by ceftazidime-treated Escherichia coli O55:B5 and subsequent production of tumor necrosis factor alpha and interleukin-1 beta. (1/736)

Treatment of septicemia caused by Escherichia coli with ceftazidime (CAZ) may be associated with the development of septic shock due to the release of bacterial lipopolysaccharide. We examined the suppressive effect of clindamycin (CLDM) on CAZ-induced release of endotoxin by cultured E. coli and the subsequent production of inflammatory cytokines (tumor necrosis factor alpha [TNF-alpha] and interleukin-1 beta [IL-1 beta]). E. coli ATCC 12014 was incubated in inactivated horse serum with or without CLDM for 1, 4, or 18 h, followed by the addition of CAZ and collection of the culture supernatant at 0, 1, and 2 h. The concentration of endotoxin in each sample was measured by a chromogenic Limulus test. Another portion of the culture supernatant was added to THP-1 cell culture and incubated for 4 h, and the concentrations of TNF-alpha and IL-1 beta in the supernatant were measured by an enzyme-linked immunosorbent assay. In the control group (no CLDM), CAZ administration resulted in significant increases in endotoxin, TNF-alpha, and IL-1 beta concentrations. Pretreatment of E. coli with CLDM for 4 or 18 h before the addition of CAZ significantly suppressed the concentrations of endotoxin, TNF-alpha, and IL-1 beta in a time-dependent manner. In addition, CAZ treatment transformed E. coli from rodshaped bacteria to filament-like structures, as determined by electron microscopy, while pretreatment with CLDM prevented these morphological changes. Our in vitro studies showed that CAZ-induced release of large quantities of endotoxin by E. coli could be suppressed by prior administration of CLDM.  (+info)

Molecular basis of AmpC hyperproduction in clinical isolates of Escherichia coli. (2/736)

DNA sequencing data showed that five clinical isolates of Escherichia coli with reduced susceptibility to ceftazidime, ceftriaxone, and cefotaxime contain an ampC gene that is preceded by a strong promoter. Transcription from the strong promoter was 8- to 18-fold higher than that from the promoter from a susceptible isolate. RNA studies showed that mRNA stability does not play a role in the control of AmpC synthesis.  (+info)

Laboratory mutants of OXA-10 beta-lactamase giving ceftazidime resistance in Pseudomonas aeruginosa. (3/736)

Several extended-spectrum beta-lactamases (ESBLs) belonging to molecular Class D have been described from Pseudomonas aeruginosa isolates collected in Turkey. Four of these, OXA-11, -14, -16 and -17, are derivatives of OXA-10 beta-lactamase. We tried to select similar mutants in vitro from OXA-10-producing transconjugants of P. aeruginosa, using a multistep method on ceftazidime-containing agars. Forty-four such mutants were obtained; all had increased resistance to ceftriaxone, cefsulodin, cefepime, cefpirome, latamoxef, aztreonam and, especially, ceftazidime whereas MICs of piperacillin, carbenicillin, cefotaxime, cefoperazone and carbapenems were little altered. Genes related to blaOXA-10 were sequenced from five mutants. One mutant enzyme had aspartate instead of glycine at position 157, and corresponded exactly to natural OXA-14 beta-lactamase. Another mutant strain appeared to have both OXA-14 and a new pI 6.2 enzyme, designated OXA-M102, with serine instead of alanine at position 124 and aspartate instead of glycine at position 157. This latter variant resembled natural OXA-16 enzyme, which has threonine at position 124 and aspartate at position 157. The remaining three mutant enzymes differed from any so far found in wild-type isolates. Two had leucine replacing tryptophan at position 154 (this enzyme was named OXA-M101) while the third (OXA-M103) had a pI of 7.6, and had lysine instead of asparagine at position 143. A different mutation at this position was previously found in OXA-11, a wild-type OXA-10 mutant. Thus, some of the ESBL mutants selected (OXA-14 and OXA-M102) correspond exactly or almost exactly to ESBLs found in wild-types, whereas others (OXA-M101 and OXA-M103) were totally new.  (+info)

Piperacillin/tazobactam plus tobramycin versus ceftazidime plus tobramycin for the treatment of patients with nosocomial lower respiratory tract infection. Piperacillin/tazobactam Nosocomial Pneumonia Study Group. (4/736)

An open-label, randomized, comparative, multi-centre study was conducted at 25 centres in the USA and Canada to compare the safety and efficacy of piperacillin/tazobactam plus tobramycin with ceftazidime plus tobramycin in patients with lower respiratory tract infections. Piperacillin/tazobactam (3 g/375 mg) every 4 h or ceftazidime (2 g) every 8 h were administered i.v. for a minimum of 5 days. Tobramycin (5 mg/kg/day) given in divided doses every 8 h was administered to all patients. Patients with Pseudomonas aeruginosa isolated from respiratory secretions at baseline were to continue tobramycin for the duration of the study. Tobramycin could be discontinued in other patients after the baseline culture results were known. A total of 300 patients was randomized, 155 into the piperacillin/tazobactam group and 145 into the ceftazidime group. Of these, 136 patients (78 in the piperacillin/tazobactam group and 58 in the ceftazidime group) were considered clinically evaluable. Both groups were comparable for age, sex, duration of treatment and other demographic features. The clinical success rate in evaluable patients was significantly greater (P = 0.006) in the piperacillin/tazobactam treatment group (58/78; 74%) than in the ceftazidime group (29/58; 50%). Eradication of the baseline pathogen was significantly greater (P = 0.003) in the piperacillin/tazobactam group (66%) than in the ceftazidime group (38%). The clinical and bacteriological responses of those patients with nosocomial pneumonia were similar to the overall results. Twelve (7.7%) piperacillin/tazobactam-treated patients and 24 (17%) ceftazidime-treated patients died during the study (P = 0.03). Seven of the 24 deaths in the ceftazidime treatment group but only one of the 12 deaths in the piperacillin/tazobactam treatment group were directly related to failure to control infection. The majority of adverse events were thought by the investigator to be attributable to the patients' underlying disease and not drug related. In this study, piperacillin/tazobactam plus tobramycin was shown to be more effective and as safe as ceftazidime plus tobramycin in the treatment of patients with nosocomial LRTI.  (+info)

In-vitro susceptibility of 1982 respiratory tract pathogens and 1921 urinary tract pathogens against 19 antimicrobial agents: a Canadian multicentre study. Canadian Antimicrobial Study Group. (5/736)

A total of 3903 pathogens from 48 Canadian medical centres were tested against 19 antimicrobial agents. Five agents showed activity against > or = 90% of all 1982 respiratory tract pathogens tested (ciprofloxacin, 90%; cefoperazone, 91%; ticarcillin/clavulanate, 92%; ceftazidime and imipenem, 93% each). Nine agents had > or = 90% activity against Enterobacteriaceae from respiratory tract infection (cefotaxime and ticarcillin/clavulanate, 90% each; aztreonam, ceftizoxime and ceftriaxone, 91% each; ceftazidime, 93%; ciprofloxacin, 97%; imipenem and netilmicin, 98% each). Similarly, five agents had activity against > or = 90% of all 1921 urinary tract pathogens tested (ciprofloxacin and ticarcillin/clavulanate, 90% each; cefoperazone and netilmicin, 91% each; imipenem, 99%). Nine agents had > or = 95% activity against Enterobacteriaceae from urinary tract infection (ciprofloxacin, 95%; cefotetan, 97%; aztreonam, cefotaxime, ceftazidime, ceftizoxime, ceftriaxone and netilmicin, 98% each; imipenem, 99%). Seventeen agents had activity against > or = 95% of Staphylococcus aureus strains. Susceptibility of Pseudomonas aeruginosa isolates ranged from 2% to 91%.  (+info)

Antibiotic dosing issues in lower respiratory tract infection: population-derived area under inhibitory curve is predictive of efficacy. (6/736)

Several lower respiratory tract infection (LRTI) trials have documented a correlation between clinical response and area under the inhibitory curve (24 h AUC/MIC; AUIC). The AUIC values in these studies were based on measured MICs and measured serum concentrations. This study evaluates AUIC estimates made using population pharmacokinetic parameters, and MICs from an automated microbiological susceptibility testing system. A computer database review over 2 years yielded 81 patients at Millard Fillmore Hospital with a culture-documented gram-negative LRTI who had been treated with piperacillin and an aminoglycoside, ceftazidime, ciprofloxacin or imipenem. Their AUIC values were estimated using renal function, drug dosages and MIC values. Outcome groups (clinical and microbiological cures and failures) were related to the AUIC values using Kruskal-Wallis ANOVA, linear regression and classification and regression tree (CART) analysis. A significant breakpoint for clinical cures was an AUIC value at least 72 SIT(-1) x 24 h (inverse serum inhibitory titre integrated over time). All antibiotics performed significantly better above this value than below it. Clinical cure was well described by a Hill-type equation. Within the piperacillin/aminoglycoside regimen, most of the activity came from the piperacillin, which had a higher overall AUIC value than the aminoglycoside. AUIC estimations based upon MIC values derived from the automated susceptibility testing method differed from NCCLS breakpoint data and from tube dilution derived values in this hospital by as much as three tube dilutions. These automated methods probably overestimated the MIC values of extremely susceptible organisms. The lack of precise MIC estimates in automated clinical microbiology methods impairs the use of AUIC to prospectively optimize microbiological outcome. Even ignoring this limitation and using the values as they are reported, the results of this analysis suggest that AUIC targets between 72 and 275 SIT(-1) x 24 h are useful in predicting clinical outcome.  (+info)

A resuscitated case from asphyxia by large bronchial cast. (7/736)

A 62-year-old woman with bronchiectasis suffered from asphyxia due to a large bronchial cast that obstructed the bronchial tree. Immediate bronchoscopic suction of a bronchial cast of 17 cm in length through the intubated tube relieved the patients without any complications. Large bronchial casts appear to be rare in this century but it should be considered in patients with acute exacerbation of excessive sputa not only in patients with asthma or allergy but also in patients with respiratory tract infection.  (+info)

Survey of extended-spectrum beta-lactamases in clinical isolates of Escherichia coli and Klebsiella pneumoniae: prevalence of TEM-52 in Korea. (8/736)

Two hundred ninety isolates of Escherichia coli were investigated for the production of extended-spectrum beta-lactamases (ESBLs). Fourteen (4.8%) of the 290 strains were found to produce ESBLs. Each of the 14 strains produced one or two ESBLs, as follows: 10 strains produced TEM-52, 1 strain produced SHV-2a, 1 strain produced SHV-12, 1 strain produced a CMY-1-like enzyme, and 1 strain expressed SHV-2a and a CMY-1-like enzyme. Another two strains for which the MICs of ceftazidime and cefoxitin were high, were probable AmpC enzyme hyperproducers. Because of the high prevalence of TEM-52 in E. coli isolates, we further investigated the TEM-type ESBLs produced by Klebsiella pneumoniae in order to observe the distribution of TEM-52 enzymes among Enterobacteriaceae in Korea. All TEM enzymes produced by 12 strains of K. pneumoniae were identified as TEM-52. To evaluate the genetic relatedness among the organisms, ribotyping of TEM-52-producing E. coli and K. pneumoniae was performed. The ribotyping profiles of the organisms showed similar but clearly different patterns. In conclusion, TEM-52 is the most prevalent TEM-type ESBL in Korea.  (+info)

Pseudomonas infections are challenging to treat due to the bacteria's ability to develop resistance against antibiotics. The treatment typically involves a combination of antibiotics and other supportive therapies, such as oxygen therapy or mechanical ventilation, to manage symptoms and prevent complications. In some cases, surgical intervention may be necessary to remove infected tissue or repair damaged organs.

Melioidosis is typically acquired through contact with contaminated soil or water in tropical and subtropical regions of Asia and Africa. The bacteria can enter the body through open wounds, cuts, or through the eyes, nose, or mouth. Once inside the body, the bacteria can multiply and cause a wide range of symptoms including fever, chills, headache, muscle and joint pain, and skin lesions.

If left untreated, melioidosis can lead to serious complications such as sepsis, meningitis, and pneumonia, which can be fatal. The disease is diagnosed through a combination of physical examination, laboratory tests, and imaging studies. Treatment typically involves antibiotics, and early treatment is essential for effective management of the disease.

In addition to being an important medical condition, melioidosis is also of interest to researchers studying the bacteria that cause the disease. Burkholderia pseudomallei has been found to have a unique ability to survive in a variety of environments, including soil and water, and has been studied for its potential as a bioterrorism agent.

In summary, melioidosis is a serious bacterial infection caused by Burkholderia pseudomallei that can affect multiple organ systems and cause severe illness if left untreated. It is typically acquired through contact with contaminated soil or water in tropical and subtropical regions of Asia and Africa and is diagnosed through a combination of physical examination, laboratory tests, and imaging studies. Early treatment is essential for effective management of the disease.

Previous article'Etiology' Next article 'Esophageal Cancer'

Klebsiella Infections can occur in anyone, but certain groups of people are at higher risk, such as premature infants, people with weakened immune systems, and those with chronic medical conditions like diabetes, liver or kidney disease.

Symptoms of Klebsiella Infections include fever, chills, cough, difficulty breathing, painful urination, redness and swelling in the affected area, and in severe cases, sepsis and death.

Diagnosis of Klebsiella Infections is typically made through a combination of physical examination, medical history, and laboratory tests, such as blood cultures and urine cultures.

Treatment of Klebsiella Infections usually involves antibiotics, which can help clear the infection and prevent it from spreading. In severe cases, hospitalization may be necessary to provide appropriate care and monitoring.

Prevention of Klebsiella Infections includes good hand hygiene, proper cleaning and disinfection of equipment and surfaces, and avoiding close contact with individuals who have the infection. Vaccines are also available for certain types of Klebsiella Infections, such as pneumonia.

Complications of Klebsiella Infections can include pneumonia, urinary tract infections, bloodstream infections, and sepsis, which can lead to organ failure and death if left untreated.

Recovery from Klebsiella Infections usually occurs within a few days to a week after antibiotic treatment is started, but in severe cases, recovery may take longer and may require hospitalization and close monitoring.

In conclusion, Klebsiella Infections are a type of bacterial infection that can affect various parts of the body, and can be mild or severe. Prompt diagnosis and treatment with antibiotics are essential to prevent complications and ensure a successful recovery. Proper hygiene practices and vaccines are also important for preventing the spread of these infections.

Bronchopneumonia is a serious condition that can lead to respiratory failure and other complications if left untreated. It is important for individuals with bronchopneumonia to seek medical attention promptly if they experience any worsening symptoms or signs of infection, such as increased fever or difficulty breathing.

Bronchopneumonia can be caused by a variety of factors, including bacterial and viral infections, and can affect individuals of all ages. It is most common in young children and the elderly, as well as those with pre-existing respiratory conditions such as asthma or chronic obstructive pulmonary disease (COPD).

Treatment for bronchopneumonia typically involves antibiotics to treat any bacterial infections, as well as supportive care to help manage symptoms and improve lung function. In severe cases, hospitalization may be necessary to provide more intensive treatment and monitoring.

In addition to antibiotics and supportive care, other treatments for bronchopneumonia may include:

* Oxygen therapy to help increase oxygen levels in the blood
* Pain management medications to relieve chest pain and fever
* Breathing exercises and pulmonary rehabilitation to improve lung function
* Rest and relaxation to help the body recover

Prevention is key in avoiding bronchopneumonia, and this can be achieved through:

* Good hand hygiene and respiratory etiquette
* Avoiding close contact with individuals who are sick
* Getting vaccinated against pneumococcal disease and the flu
* Practicing good hygiene during travel to avoid exposure to respiratory infections.

In conclusion, bronchopneumonia is a serious condition that can be caused by a variety of factors and can affect individuals of all ages. Treatment typically involves antibiotics and supportive care, and prevention strategies include good hygiene practices and vaccination. With proper treatment and care, individuals with bronchopneumonia can recover and lead active lives.

Some common examples of bacterial infections include:

1. Urinary tract infections (UTIs)
2. Respiratory infections such as pneumonia and bronchitis
3. Skin infections such as cellulitis and abscesses
4. Bone and joint infections such as osteomyelitis
5. Infected wounds or burns
6. Sexually transmitted infections (STIs) such as chlamydia and gonorrhea
7. Food poisoning caused by bacteria such as salmonella and E. coli.

In severe cases, bacterial infections can lead to life-threatening complications such as sepsis or blood poisoning. It is important to seek medical attention if symptoms persist or worsen over time. Proper diagnosis and treatment can help prevent these complications and ensure a full recovery.

Gram-negative bacterial infections can be difficult to treat because these bacteria are resistant to many antibiotics. In addition, some gram-negative bacteria produce enzymes called beta-lactamases, which break down the penicillin ring of many antibiotics, making them ineffective against the infection.

Some common types of gram-negative bacterial infections include:

* Pneumonia
* Urinary tract infections (UTIs)
* Bloodstream infections (sepsis)
* Meningitis
* Skin and soft tissue infections
* Respiratory infections, such as bronchitis and sinusitis

Examples of gram-negative bacteria that can cause infection include:

* Escherichia coli (E. coli)
* Klebsiella pneumoniae
* Pseudomonas aeruginosa
* Acinetobacter baumannii
* Proteus mirabilis

Gram-negative bacterial infections can be diagnosed through a variety of tests, including blood cultures, urine cultures, and tissue samples. Treatment typically involves the use of broad-spectrum antibiotics, such as carbapenems or cephalosporins, which are effective against many types of gram-negative bacteria. In some cases, the infection may require hospitalization and intensive care to manage complications such as sepsis or organ failure.

Prevention of gram-negative bacterial infections includes good hand hygiene, proper use of personal protective equipment (PPE), and appropriate use of antibiotics. In healthcare settings, infection control measures such as sterilization and disinfection of equipment, and isolation precautions for patients with known gram-negative bacterial infections can help prevent the spread of these infections.

Overall, gram-negative bacterial infections are a significant public health concern, and proper diagnosis and treatment are essential to prevent complications and reduce the risk of transmission.

This condition can be caused by various factors such as genetic mutations, infections, autoimmune disorders, and certain medications. In severe cases, agranulocytosis can lead to life-threatening infections that require prompt medical treatment.

Some of the common symptoms of agranulocytosis include fever, chills, sore throat, fatigue, and recurring infections. Diagnosis is typically made through blood tests that measure the number and function of white blood cells, including granulocytes. Treatment options for agranulocytosis depend on the underlying cause, but may include antibiotics, antiviral medications, and immunoglobulin replacement therapy in severe cases.

There are different types of fever, including:

1. Pyrexia: This is the medical term for fever. It is used to describe a body temperature that is above normal, usually above 38°C (100.4°F).
2. Hyperthermia: This is a more severe form of fever, where the body temperature rises significantly above normal levels.
3. Febrile seizure: This is a seizure that occurs in children who have a high fever.
4. Remittent fever: This is a type of fever that comes and goes over a period of time.
5. Intermittent fever: This is a type of fever that recurs at regular intervals.
6. Chronic fever: This is a type of fever that persists for an extended period of time, often more than 3 weeks.

The symptoms of fever can vary depending on the underlying cause, but common symptoms include:

* Elevated body temperature
* Chills
* Sweating
* Headache
* Muscle aches
* Fatigue
* Loss of appetite

In some cases, fever can be a sign of a serious underlying condition, such as pneumonia, meningitis, or sepsis. It is important to seek medical attention if you or someone in your care has a fever, especially if it is accompanied by other symptoms such as difficulty breathing, confusion, or chest pain.

Treatment for fever depends on the underlying cause and the severity of the symptoms. In some cases, medication such as acetaminophen (paracetamol) or ibuprofen may be prescribed to help reduce the fever. It is important to follow the recommended dosage instructions carefully and to consult with a healthcare professional before giving medication to children.

In addition to medication, there are other ways to help manage fever symptoms at home. These include:

* Drinking plenty of fluids to stay hydrated
* Taking cool baths or using a cool compress to reduce body temperature
* Resting and avoiding strenuous activities
* Using over-the-counter pain relievers, such as acetaminophen (paracetamol) or ibuprofen, to help manage headache and muscle aches.

Preventive measures for fever include:

* Practicing good hygiene, such as washing your hands frequently and avoiding close contact with people who are sick
* Staying up to date on vaccinations, which can help prevent certain infections that can cause fever.

Endophthalmitis can be classified into several types based on its causes, such as:

1. Postoperative endophthalmitis: This type of endophthalmitis occurs after cataract surgery or other intraocular surgeries. It is caused by bacterial infection that enters the eye through the surgical incision.
2. Endogenous endophthalmitis: This type of endophthalmitis is caused by an infection that originates within the eye, such as from a retinal detachment or uveitis.
3. Exogenous endophthalmitis: This type of endophthalmitis is caused by an infection that enters the eye from outside, such as from a penetrating injury or a foreign object in the eye.

The symptoms of endophthalmitis can include:

1. Severe pain in the eye
2. Redness and swelling of the conjunctiva
3. Difficulty seeing or blind spots in the visual field
4. Sensitivity to light
5. Increased sensitivity to touch or pressure on the eye
6. Fever and chills
7. Swollen lymph nodes
8. Enlarged pupil
9. Clouding of the vitreous humor

If you suspect that you or someone else has endophthalmitis, it is important to seek medical attention immediately. Early diagnosis and treatment can help prevent vision loss. Treatment options for endophthalmitis may include antibiotics, vitrectomy (removal of the vitreous humor), and in some cases, removal of the affected eye.

In medicine, cross-infection refers to the transmission of an infectious agent from one individual or source to another, often through direct contact or indirect exposure. This type of transmission can occur in various settings, such as hospitals, clinics, and long-term care facilities, where patients with compromised immune systems are more susceptible to infection.

Cross-infection can occur through a variety of means, including:

1. Person-to-person contact: Direct contact with an infected individual, such as touching, hugging, or shaking hands.
2. Contaminated surfaces and objects: Touching contaminated surfaces or objects that have been touched by an infected individual, such as doorknobs, furniture, or medical equipment.
3. Airborne transmission: Inhaling droplets or aerosolized particles that contain the infectious agent, such as during coughing or sneezing.
4. Contaminated food and water: Consuming food or drinks that have been handled by an infected individual or contaminated with the infectious agent.
5. Insect vectors: Mosquitoes, ticks, or other insects can transmit infections through their bites.

Cross-infection is a significant concern in healthcare settings, as it can lead to outbreaks of nosocomial infections (infections acquired in hospitals) and can spread rapidly among patients, healthcare workers, and visitors. To prevent cross-infection, healthcare providers use strict infection control measures, such as wearing personal protective equipment (PPE), thoroughly cleaning and disinfecting surfaces, and implementing isolation precautions for infected individuals.

In summary, cross-infection refers to the transmission of an infectious agent from one individual or source to another, often through direct contact or indirect exposure in healthcare settings. Preventing cross-infection is essential to maintaining a safe and healthy environment for patients, healthcare workers, and visitors.

... is available as a generic medication. Ceftazidime is used to treat lower respiratory tract, skin, urinary tract, ... Ceftazidime/avibactam "Ceftazidime". The American Society of Health-System Pharmacists. Archived from the original on 20 ... Ceftazidime is contraindicated in people with a known allergy to ceftazidime or to any other cephalosporin antibiotic. ... Ceftazidime is mainly eliminated by the kidneys into the urine. As such, drug levels in the blood may build up in persons with ...
Richards DM, Brogden RN (February 1985). "Ceftazidime. A review of its antibacterial activity, pharmacokinetic properties and ... and ceftazidime for bacterial infections, zidovudine for HIV infection, valacyclovir for herpes virus infections, albendazole ...
Ceftazidime "Cefotaxime". Merriam-Webster Dictionary. Retrieved 21 January 2016. "Cefotaxime (Claforan) Use During Pregnancy". ...
Hughes, SP; McCarthy, ID; Fleming, RM; Anderson, FM; Dash, CH (1984). "Extraction of ceftazidime in bone". J Antimicrob ...
The antibiotic of choice is ceftazidime. While various antibiotics are active in vitro (e.g., chloramphenicol, doxycycline, co- ... "Halving of mortality of severe melioidosis by ceftazidime". Lancet. 2 (8665): 697-701. doi:10.1016/S0140-6736(89)90768-X. PMID ...
Smith BR (1984). "Cefsulodin and ceftazidime, two antipseudomonal cephalosporins". Clinical Pharmacy. 3 (4): 373-85. PMID ...
Lifshitz T, Lapid-Gortzak R, Finkelman Y, Klemperer I (January 2000). "Vancomycin and ceftazidime incompatibility upon ...
There, he helped develop the antibiotic ceftazidime. In 1977 he left Glaxo and was recruited to the United States by the Squibb ... By modifying the amide side chain and including a ceftazidime side chain, he produced aztreonam, the first monocyclic β-lactam ... where he helped develop the antibiotic ceftazidime. Subsequently, he was recruited by the Squibb Institute, in the United ...
cefepime, ceftazidime, imipenem, meropenem or piperacillin-tazobactam; plus ciprofloxacin, levofloxacin, amikacin, gentamicin, ... A third generation cephalosporin (ceftazidime) + carbapenems (imipenem) + beta lactam & beta lactamase inhibitors (piperacillin ...
It is usually susceptible to piperacillin and ceftazidime. Tigecycline is also an effective drug. Polymyxin B may be effective ...
Ceftazidime had been shown to reduce the risk of death of melioidosis from 74% to 37%. In 1990, a non-virulent 'arabinose- ... Intravenous ceftazidime is the current drug of choice for treatment of acute melioidosis and should be administered for at ... November 1994). "Ceftazidime vs. amoxicillin/clavulanate in the treatment of severe melioidosis". Clinical Infectious Diseases ... According to the 2020 Revised Royal Darwin Hospital Guideline, the dosage for intravenous ceftazidime is 2g 6-hourly in adults ...
... except for patients with a ceftazidime allergy as ceftazidime and aztreonam share a similar side chain). It is also frequently ... However, there is a higher chance of cross-sensitivity if a person is specifically allergic to ceftazidime, a cephalosporin. ... Aztreonam exhibits cross-sensitivity with ceftazidime due to a similar side chain. Aztreonam is similar in action to penicillin ... In these circumstances aztreonam is combined with avibactam (ceftazidime/avibactam). The combination of aztreonam and avibactam ...
Initial treatment typically includes antibiotics such as vancomycin, ceftriaxone or ceftazidime. Surgery in the form of joint ... ceftazidime +/- an aminoglycoside Once cultures are available, antibiotics can be changed to target the specific organism. ... or ceftazidime Gram stain negative and immunocompetent - vancomycin Gram stain negative and immunocompromised - vancomycin + ...
1990). "Efficacy of ceftazidime in the treatment of acute pelvic infections". Niger Med. Pract. 20 (4): 77-78. Omigbodun, AO; ...
Vancomycin plus ceftazidime cover infections caused by common organisms (e.g. Bacillus species, coagulase-negative ...
Studies has shown Anaerococcus prevotii presents resistance to Ceftazidime, Clindamycin, Levofloxacin. Unlike the other species ...
Ceftazidime, ofloxacin, trimethoprim and chloramphenicol have all been shown to induce filamentation. Treatment at or below the ...
Despite their name, a few are more active on ceftazidime than cefotaxime. They have mainly been found in strains of Salmonella ... Ceftriaxone, cefotaxime, and ceftazidime have failed even more often, despite the organism's susceptibility to the antibiotic ... Some confer resistance predominantly to ceftazidime, but OXA-17 confers greater resistance to cefotaxime and cefepime than it ... These cephalosporins include cefotaxime, ceftriaxone, and ceftazidime, as well as the oxyimino-monobactam aztreonam. Thus ESBLs ...
Treatment was ceftazidime and intravenous (IV) ciprofloxacin and IV doxycycline, which proved successful. Prevention of ... recommend treating the person with a quinolone or intravenous doxycycline with ceftazidime. The first successful documented ...
... ceftazidime, and metoclopramide. R.D. Adams and J.M. Foley first described asterixis in 1949 in patients with severe liver ...
"Taxonomic characterisation of ceftazidime-resistant Brevundimonas isolates and description of Brevundimonas faecalis sp. nov". ...
However, unlike ceftazidime and cefoperazone, ceftriaxone does not have useful activity against Pseudomonas aeruginosa. It is ...
Ceftazidime/avibactam (ceftazidime/NXL104): antipseudomonal cephalosporin/β-lactamase inhibitor combination (cell wall ... New cephalosporin-lactamase inhibitor combinations also approved include ceftazidime-avibactam and ceftolozane-avibactam for ...
Glaxo drugs that sold well included the Fortum (ceftazidime) and Zinnat (cefuroxime axetil) antibiotics. He married in 1952; ...
... ceftazidime, or cefepime) plus metronidazole •Monotherapy with piperacillin-tazobactam •Monotherapy with meropenem Vancomycin ...
Avison, M. B. (2004). "Analysis of AmpC -lactamase expression and sequence in biochemically atypical ceftazidime-resistant ...
Newer beta-lactam / beta-lactamase combinations like ceftazidime-avibactam or ceftolozane-tazobactam can also be effective. ... ceftazidime, minocycline, piperacillin, and meropenem are considered to be viable alternative options in cases where co- ... Treatment typically includes multiple antibiotics and may include ceftazidime, minocycline, piperacillin, meropenem, ...
The team starts Jordan on high-dose ceftazidime for the vibrio and chelate for the hemochromatosis. Jordan also admits that she ...
Injections of vancomycin (to kill Gram-positive bacteria) and ceftazidime (to kill Gram-negative bacteria) are routine. Even ...
Some common antibiotics administered nowadays are vancomycin (for Gram-positive bacteria) and ceftazidime (for Gram-negative ...
CEFTAZIDIME (UNII: 9M416Z9QNR) (CEFTAZIDIME ANHYDROUS - UNII:DZR1ENT301) CEFTAZIDIME ANHYDROUS. 1 g in 20 mL. ... CEFTAZIDIME (UNII: 9M416Z9QNR) (CEFTAZIDIME ANHYDROUS - UNII:DZR1ENT301) CEFTAZIDIME ANHYDROUS. 2 g in 20 mL. ... Ceftazidime for Injection. To reduce the development of drug-resistant bacteria and maintain the effectiveness of ceftazidime ... Ceftazidime is a bactericidal agent that acts by inhibition of bacterial cell wall synthesis. Ceftazidime has activity in the ...
Ceftazidime Injection: learn about side effects, dosage, special precautions, and more on MedlinePlus ... Take ceftazidime injection until you finish the prescription, even if you feel better. If you stop taking ceftazidime injection ... Before taking ceftazidime injection,. *tell your doctor and pharmacist if you are allergic to ceftazidime, other cephalosporin ... Ceftazidime injection may cause side effects. Tell your doctor if any of these symptoms are severe or do not go away: *pain, ...
Your search for CEFTAZIDIME ANHYDROUS did not return any results. Your search may be too specific. Try using fewer or broader ...
"ceftazidime"[All Fields] OR ("ceftazidime"[All Fields] AND "anhydrous"[All Fields]). Search. ...
Limited information indicates that ceftazidime produces low levels in milk that are not expected to cause adverse effects in ... Ceftazidime and Avibactam No authors listed In: Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National ... Ceftazidime. [No authors listed] [No authors listed] 2018 Oct 31. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda ... Ceftazidime levels in human breast milk. Antimicrob Agents Chemother. 1983;23:479-80. - PMC - PubMed ...
Limited information indicates that ceftazidime produces low levels in milk that are not expected to cause adverse effects in ... Ceftazidime and Avibactam No authors listed In: Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National ... Ceftazidime. [No authors listed] [No authors listed] 2018 Oct 31. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda ... Ceftazidime levels in human breast milk. Antimicrob Agents Chemother. 1983;23:479-80. - PMC - PubMed ...
Ceftazidime-Resistant Salmonella enterica, Morocco. Volume 15, Number 10-October 2009. Article Views: 258. Data is collected ... Ceftazidime-Resistant Salmonella enterica, Morocco. Emerging Infectious Diseases. 2009;15(10):1693-1695. doi:10.3201/ ... The isolate was resistant to penicillins, cefoxitin (MIC 128 mg/L), ceftriaxone (MIC 64 mg/L), ceftazidime (MIC 128 mg/L), ... Bouchrif, B., Le Hello, S., Pardos, M., Karraouan, B., Perrier-Gros-Claude, J., Ennaji, M....Weill, F. (2009). Ceftazidime- ...
Pharmacokinetics of ceftazidime in loggerhead sea turtles (Caretta caretta) after single intravenous and intramuscular ... Pharmacokinetics of ceftazidime in loggerhead sea turtles (Caretta caretta) after single intravenous and intramuscular ... Pharmacokinetics of ceftazidime in loggerhead sea turtles (Caretta caretta) after single intravenous and intramuscular ...
Dynamic Emergence of Pseudomonas aeruginosa Hypermutation and Ceftazidime-Avibactam Resistance in Acute Systemic Infection. ... during the course of an acute systemic infection in a single patient in which both a hypermutator phenotype and ceftazidime- ...
cefTAZidime Launches SteriMax is pleased to announce the launch of cefTAZidime for Injection BP in 1 g, 2 g, 3 g, and 6 g ...
CefTAZidime published on Jun 2018 by American Society of Health-System Pharmacists. ...
Ceftazidime is a third-generation cephalosporin with broad-spectrum, gram-negative activity, including against pseudomonas; it ...
CEFTAZIDIME (UNII: 9M416Z9QNR) (CEFTAZIDIME ANHYDROUS - UNII:DZR1ENT301) CEFTAZIDIME ANHYDROUS. 2 g. AVIBACTAM SODIUM (UNII: ... ceftazidime and avibactam) for injection *Ceftazidime 2 gram (equivalent to 2.635 g ceftazidime pentahydrate/sodium carbonate) ... Dose for AVYCAZ (ceftazidime and avibactam)c. Frequency. 31 to 50. AVYCAZ 31.25 mg/kg to a maximum of 1.25 grams (Ceftazidime ... Dose for AVYCAZ (ceftazidime and avibactam)b Frequency. 31 to 50. AVYCAZ 1.25 grams (ceftazidime 1 gram and avibactam 0.25 ...
Ceftazidime Avibactam Aztreonam Manufacturers, Factory, Suppliers From China, We, with great passion and faithfulness, are ... Ceftazidime Avibactam Aztreonam. Ceftazidime Avibactam Aztreonam - Factory, Suppliers, Manufacturers from China. Our ... excellent talents and continuously strengthened technology forces for Ceftazidime Avibactam Aztreonam, Intermediate Of ...
Ceftazidime-avibactam (CAZ-AVI) and polymyxins are considered as the last therapeutic options worldwide. This is the first meta ... Efficacy and safety of ceftazidime-avibactam versus polymyxins in the treatment of carbapenem-resistant Enterobacteriaceae ... Efficacy and safety of ceftazidime-avibactam versus polymyxins in the treatment of carbape ...
Ceftazidime. 2013-2014. 0.016-256†. ≤4. 8. ≥16. Ceftiofur. 2015. 0.12-8. No CLSI or NARMS breakpoints. ...
Ceftazidime <=1.0. S. Ceftazidime/avibactam 1. <=0.5. S. Ceftazidime/clavulanic acid 1. <=0.5. ---. ...
Ceftazidime/avibactam. 2015. Intra-abdominal infection; urinary tract infection. Yes. a ESKAPE pathogens: Enterococcus faecium ...
2010avycaz-ceftazidime-avibactam-999985. Drugs ceftazidime/avibactam * 2010invanz-ertapenem-342561. Drugs ertapenem ...
Detailed drug Information for Aviane. Includes common brand names, drug descriptions, warnings, side effects and dosing information.
The MIC of ceftazidime and neomycin in combination with S. limbata was reduced fourfold for each antibiotic. Conclusion: Salvia ... Checkerboard assay was used to evaluate the synergistic effect of the extracts with ceftazidime and neomycin. Results: Salvia ... The fractional inhibitory concentration (FIC) results showed partial synergistic activity between S. limbata with ceftazidime ... We also examined the synergistic effect of these extracts with ceftazidime and neomycin. The antimicrobial effects of these ...
Find information on Furosemide (Lasix) in Daviss Drug Guide including dosage, side effects, interactions, nursing implications, mechanism of action, half life, administration, and more. Davis Drug Guide PDF.
Intravenous ceftazidime is the current drug of choice for treatment of acute melioidosis and should be administered for at ... November 1994). "Ceftazidime vs. amoxicillin/clavulanate in the treatment of severe melioidosis". Clinical Infectious Diseases ... White NJ, Dance DA, Chaowagul W, Wattanagoon Y (1989). "Halving of mortality of severe melioidosis by ceftazidime". The Lancet ... According to the 2020 Revised Royal Darwin Hospital Guideline, the dosage for intravenous ceftazidime is 2g 6-hourly in adults ...
Ceftazidime-Avibactam, Others), Penicillins (Generic amoxicillin, Augmentin, Zosyn/Tazocin, Unasyn, Generic Amoxicllin- ... Ceftazidime-Avibactam. By Penicillins. • Generic Amoxicillin. • Augmentin. • Zosyn/Tazocin. • Unasyn. • Generic amoxicllin- ... 5.9 Zavicefta (CAZ-AVI) (Ceftazidime-Avibactam) Segment: Revenue Forecast, 2020-2030 (US$ Mn, AGR%, CAGR%). 5.10 Others Segment ... Figure 48 Global Antibacterial Drugs Market for Ceftazidime-Avibactam Segment: Revenue Forecast 2020-2030 (US$ million, AGR%). ...
Cefepime and ceftazidime safety in hospitalized infants. The Pediatric Infectious Disease Journal, 34(9), 964-968. PMID: ...
... ceftazidime, ceftriaxone or cefotaxime; Empiric antibiotics for fever and neutropenia = imipenem, meropenem, cefepime, ... ceftazidime or piperacillin/tazobactam. *Comparison of the Percentage of Patients Having Incidence of Fever and Febrile ...
Ceftazidime--therapeutic use. Drug Resistance, Bacterial--drug effects. Pseudomonas Infections--drug therapy. Pseudomonas ...
  • Ceftazidime and Avibactam. (nih.gov)
  • Ceftazidime-avibactam is acceptable in nursing mothers. (nih.gov)
  • In this work, we apply genomic sequencing to 9 serially-collected P. aeruginosa isolates cultured during the course of an acute systemic infection in a single patient in which both a hypermutator phenotype and ceftazidime-avibactam (CZA) resistance rapidly emerged in vivo. (nih.gov)
  • AVYCAZ 2.5g (ceftazidime and avibactam) for injection is supplied as a sterile powder for constitution in single-dose vials containing ceftazidime 2 grams (equivalent to 2.635 grams of ceftazidime pentahydrate/sodium carbonate powder) and avibactam 0.5 grams (equivalent to 0.551 grams of avibactam sodium). (nih.gov)
  • Efficacy and safety of ceftazidime-avibactam versus polymyxins in the treatment of carbapenem-resistant Enterobacteriaceae infection: a systematic review and meta-analysis. (bvsalud.org)
  • Ceftazidime -avibactam (CAZ-AVI) and polymyxins are considered as the last therapeutic options worldwide. (bvsalud.org)
  • Ceftazidime for injection, USP in sterile crystalline form is supplied in single-dose vials equivalent to 1 g or 2 g of anhydrous ceftazidime. (nih.gov)
  • Your search for CEFTAZIDIME ANHYDROUS did not return any results. (nih.gov)
  • To reduce the development of drug-resistant bacteria and maintain the effectiveness of ceftazidime for injection and other antibacterial drugs, ceftazidime for injection should be used only to treat infections that are proven or strongly suspected to be caused by bacteria. (nih.gov)
  • Ceftazidime for injection, USP is a sterile, dry-powdered mixture of ceftazidime pentahydrate and sodium carbonate. (nih.gov)
  • Ceftazidime for injection, USP is a white to cream-colored crystalline powder. (nih.gov)
  • Solutions of ceftazidime for injection, USP range in color from light yellow to amber, depending on the diluent and volume used. (nih.gov)
  • Ceftazidime injection is in a class of medications called cephalosporin antibiotics. (medlineplus.gov)
  • Antibiotics such as ceftazidime injection will not work for colds, flu, or other viral infections. (medlineplus.gov)
  • Ceftazidime injection comes as a powder to be mixed with liquid and given intravenously (into a vein) or intramuscularly (into a muscle). (medlineplus.gov)
  • Ceftazidime injection is also available as a premixed product to be injected intravenously. (medlineplus.gov)
  • You may receive ceftazidime injection in a hospital or you may administer the medication at home. (medlineplus.gov)
  • If you will be receiving ceftazidime injection at home, your healthcare provider will show you how to use the medication. (medlineplus.gov)
  • You should begin to feel better during the first few days of treatment with ceftazidime injection. (medlineplus.gov)
  • Take ceftazidime injection until you finish the prescription, even if you feel better. (medlineplus.gov)
  • If you stop taking ceftazidime injection too soon or skip doses, your infection may not be completely treated and the bacteria may become resistant to antibiotics. (medlineplus.gov)
  • Ceftazidime injection is also sometimes used to treat patients who have a fever and are at high risk for infection because they have a low number of white blood cells, melioidosis (a serious infection that is common in places with a tropical climate), certain wound infections, and food poisoning. (medlineplus.gov)
  • Also tell your doctor if you are allergic to any of the ingredients in ceftazidime injection. (medlineplus.gov)
  • you should know that ceftazidime injection decreases the effectiveness of some oral contraceptives ('birth control pills). (medlineplus.gov)
  • If you become pregnant while taking ceftazidime injection, call your doctor. (medlineplus.gov)
  • Ceftazidime injection may cause side effects. (medlineplus.gov)
  • To learn more visit the cefTAZidime for Injection product page. (sterimaxinc.com)
  • For example, a 500 MG single-use vial of ceftazidime will have 'Ceftazidime 500 MG Injection' as a normalized name. (nih.gov)
  • [1] Those with melioidosis are treated first with an "intensive phase" course of intravenous antibiotics (most commonly ceftazidime ) followed by a several-month treatment course of co-trimoxazole . (wikipedia.org)
  • Clinical evaluation of meropenem versus ceftazidime for the treatment of Pseudomonas spp. (medscape.com)
  • Klebsiella pneumoniae ( K . pneumoniae ) is the leading pathogen globally underlying cases of neonatal sepsis and is frequently resistant to antibiotic treatment regimens recommended by the World Health Organization (WHO), including first-line therapy with ampicillin and gentamicin, second-line therapy with amikacin and ceftazidime, and meropenem. (plos.org)
  • Isolates were resistant to penicillins and ceftazidime but were susceptible to other antimicrobial drug classes tested. (cdc.gov)
  • The presence of hepatic dysfunction had no effect on the pharmacokinetics of ceftazidime in individuals administered 2 g intravenously every 8 hours for 5 days. (nih.gov)
  • The antimicrobial effects of these plants had been reported before but synergistic effect with broad spectrum antibiotics such as ceftazidime and neomycin was an important issue that we tried to determine. (rjpharmacognosy.ir)
  • The sodium carbonate at a concentration of 118 mg/g of ceftazidime activity has been admixed to facilitate dissolution. (nih.gov)
  • Comparison with ceftriaxone, cefotaxime, latamoxef and ceftazidime]. (nih.gov)
  • Isolates showed higher levels of resistance to ceftazidime (MIC 128 mg/L) than to ceftriaxone (MIC 8 mg/L). (cdc.gov)
  • Development of Ceftazidime Resistance in Burkhoderia pseudomallei in a Patient Experiencing Melioidosis with Mediastinal. (annals.edu.sg)
  • Salvia limbata is a potentially rich source of bioactive compounds with antimicrobial properties that can be used with ceftazidime and neomycin to provide a synergistic effect. (rjpharmacognosy.ir)
  • After IV administration of 500 mg and 1 g doses of ceftazidime over 5 minutes to normal adult male volunteers, mean peak serum concentrations of 45 and 90 mcg/ mL, respectively, were achieved. (nih.gov)
  • After IV infusion of 500 mg, 1 g, and 2 g doses of ceftazidime over 20 to 30 minutes to normal adult male volunteers, mean peak serum concentrations of 42, 69, and 170 mcg/mL, respectively, were achieved. (nih.gov)
  • There was no evidence of accumulation of ceftazidime in the serum in individuals with normal renal function following multiple IV doses of 1 and 2 g every 8 hours for 10 days. (nih.gov)
  • Following intramuscular (IM) administration of 500 mg and 1 g doses of ceftazidime to normal adult volunteers, the mean peak serum concentrations were 17 and 39 mcg/mL, respectively, at approximately 1 hour. (nih.gov)
  • The total sodium content of the mixture is approximately 54 mg (2.3 mEq)/g of ceftazidime activity. (nih.gov)
  • The fractional inhibitory concentration (FIC) results showed partial synergistic activity between S. limbata with ceftazidime and neomycin against P. aeruginosa and MRSA. (rjpharmacognosy.ir)
  • Limited information indicates that ceftazidime produces low levels in milk that are not expected to cause adverse effects in breastfed infants. (nih.gov)
  • The half-life of ceftazidime in these volunteers was approximately 2 hours. (nih.gov)
  • The MIC of ceftazidime and neomycin in combination with S. limbata was reduced fourfold for each antibiotic. (rjpharmacognosy.ir)
  • The elimination of ceftazidime by the kidneys resulted in high therapeutic concentrations in the urine. (nih.gov)
  • Ceftazidime is a semisynthetic, broad-spectrum, beta-lactam antibacterial drug for parenteral administration. (nih.gov)
  • Ceftazidime injection is in a class of medications called cephalosporin antibiotics. (medlineplus.gov)
  • On March 18, 2019, the Food and Drug Administration (FDA) extended approval for ceftazidime-avibactam to pediatric patients 3 months of age and older for the treatment of complicated intra-abdominal infections (cIAI) in combination with metronidazole and the treatment of complicated urinary tract infections (cUTI) including pyelonephritis. (medscape.com)
  • Ceftazidime for injection, USP is a sterile, dry-powdered mixture of ceftazidime pentahydrate and sodium carbonate. (nih.gov)
  • AVYCAZ 2.5g (ceftazidime and avibactam) for injection is supplied as a sterile powder for constitution in single-dose vials containing ceftazidime 2 grams (equivalent to 2.635 grams of ceftazidime pentahydrate/sodium carbonate powder) and avibactam 0.5 grams (equivalent to 0.551 grams of avibactam sodium). (nih.gov)
  • She was found to have persistent osteomyelitis and started on ceftazidime for a culture documented Pseudomonas aeruginosa infection. (nih.gov)
  • Cefepime and ceftazidime are cephalosporins used for the treatment of serious Gram-negative infections. (nih.gov)
  • [ 1 ] Ceftazidime-avibactam was first approved in 2015 for adults with cIAI and cUTI, and was subsequently approved for the treatment of hospital-acquired or ventilator-associated pneumonia in February 2018. (medscape.com)
  • We identified all infants discharged from 348 neonatal intensive care units managed by the Pediatrix Medical Group between 1997 and 2012 who were exposed to either cefepime or ceftazidime in the first 120 days of life. (nih.gov)
  • We reported clinical and laboratory adverse events occurring in infants exposed to cefepime or ceftazidime and used multivariable logistic regression to compare the odds of seizures and death between the 2 groups. (nih.gov)
  • A total of 1761 infants received 13,293 days of ceftazidime, and 594 infants received 4628 days of cefepime. (nih.gov)
  • Seizure was the most commonly observed clinical adverse event, occurring in 3% of ceftazidime-treated infants and 4% of cefepime-treated infants (P = 0.52). (nih.gov)
  • Gram-negative coverage comparable to that of ceftazidime but has better gram-positive coverage (comparable to ceftriaxone). (medscape.com)
  • The presence of hepatic dysfunction had no effect on the pharmacokinetics of ceftazidime in individuals administered 2 g intravenously every 8 hours for 5 days. (nih.gov)
  • Ceftazidime is a semisynthetic, broad-spectrum, beta-lactam antibacterial drug for parenteral administration. (nih.gov)
  • Clinical efficacy of ceftazidime combined with levofloxacin on heart failure complicated with pulmonary infection and its influence on cardiopulmonary function. (bvsalud.org)
  • This study was designed to analyze the clinical efficacy of ceftazidime combined with levofloxacin on heart failure complicated with pulmonary infection and its influence on cardiopulmonary function. (bvsalud.org)
  • To sum up, ceftazidime combined with levofloxacin on patients with heart failure and pulmonary infection can improve the immune function while optimizing the clinical efficacy and cardiopulmonary function. (bvsalud.org)
  • Isolates were resistant to penicillins and ceftazidime but were susceptible to other antimicrobial drug classes tested. (cdc.gov)
  • Still, the most likely culprit was ceftazidime, a rare cause of drug induced liver injury with very few reports in the literature. (nih.gov)
  • Due to rapid identification, all medications with potential hepatotoxicity, including ceftazidime, were discontinued and the LFTs promptly returned to baseline over 3 days. (nih.gov)
  • Since ceftazidime is eliminated almost solely by the kidneys, its serum half-life is significantly prolonged in patients with impaired renal function. (nih.gov)
  • The calculated plasma clearance of approximately 115 mL/min indicated nearly complete elimination of ceftazidime by the renal route. (nih.gov)
  • Your search for CEFTAZIDIME ANHYDROUS did not return any results. (nih.gov)
  • The total sodium content of the mixture is approximately 54 mg (2.3 mEq)/g of ceftazidime activity. (nih.gov)